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Molecular diagnostic tools with non-invasive properties that allow detection of pathological
events in Alzheimer’s disease (AD) and other neurodegenerative tauopathies are
essential for the development of therapeutics. Several diagnostic strategies based on
the identification of biomarkers have been proposed. However, its specificity among
neurodegenerative disorders is disputable as the association with pathological events
remains elusive. Recently, we showed that Amphiphysin-1 (AMPH1) protein’s abundance
is reduced in the central nervous system (CNS) of the tauopathy mouse model
JNPL3 and AD brains. AMPH1 is a synaptic protein that plays an important role in
clathrin-mediated endocytosis and associates with BIN1, one of the most important
risk loci for AD. Also, it has been associated with a rare neurological disease known
as Stiff-Person Syndrome (SPS). Auto-antibodies against AMPH1 are used as diagnostic
biomarkers for a paraneoplastic variant of SPS. Therefore, we set up to evaluate the
presence and abundance of auto-AMPH1 antibodies in tau-mediated neurodegeneration.
Immunoblots and enzyme-linked immunosorbent assays (ELISA) were conducted to
detect the presence of auto-AMPH1 antibodies in sera from euthanized mice that
developed neurodegeneration (JNPL3) and healthy control mice (NTg). Results showed
increased levels of auto-AMPH1 antibodies in JNPL3 sera compared to NTg controls.
The abundance of auto-AMPH1 antibodies correlated with motor impairment and AMPH1
protein level decrease in the CNS. The results suggest that auto-AMPH1 antibodies could
serve as a biomarker for the progression of tau-mediated neurodegeneration in JNPL3
mice.
Keywords: Alzheimer’s disease, tauopathies, tau-mediated neurodegeneration, autoimmune response,
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INTRODUCTION
Tauopathies are a group of neurodegenerative disorders that
present cognitive and/or motor deficits associated to modifica-
tions and oligomerization of the microtubule-associated protein
tau. Alzheimer’s disease (AD) is themost common and intensively
studied tauopathy because of its prevalence, severity, and care
costs (Steenland et al., 2009). These facts instigate special atten-
tion to AD’s etiology and associated molecular mechanisms to
identify potential diagnostic and therapeutic strategies. At present
time, AD diagnosis is possible at mid to late stages of progres-
sion when symptoms can be clearly identified by physicians using
the available psychometric tests. However, approximately 10% of
the cases can be unrecognized by most experienced physicians
and related neurodegenerative disorders could be misidentified
as AD (Beach et al., 2012). Other diagnostic strategies consist of
neuroimaging techniques with high costs and yet unproven accu-
racy (McKhann et al., 2011). Additional diagnostic tools are based
on the detection of disease biomarkers in cerebrospinal fluid
(CSF) collected by lumbar puncture, a painful and invasive proce-
dure that can cause serious health complications (Blennow et al.,
2012). Therefore, it is imperative to identify accurate biomarkers
of tau-mediated neurodegeneration with non-invasive properties
in order to develop definitive diagnostic tools for AD and related
disorders.
Previously, we reported that the abundance of the synaptic
protein Amphiphysin-1 (AMPH1) is reduced in the central ner-
vous system (CNS) of the JNPL3 tauopathy mouse model and
AD brains (De Jesus-Cortes et al., 2012). The putative patho-
logical significance of AMPH1 protein level reduction relies on
the key role it plays in clathrin-mediated synaptic vesicle endocy-
tosis, an essential event for synaptic function (Wu et al., 2009).
Consistently, AMPH1 knockout (KO) mice shows decreased
synaptic vesicle recycling and cognitive impairment which is
a clinical feature in AD (Di Paolo et al., 2002). Deletion of
AMPH1 is accompanied by decreased expression of AMPH2, also
known as BIN1. Interestingly, single nucleotide polymorphism
at BIN1 has recently been identified as one of the most impor-
tant risk factors for late-onset AD (Bertram et al., 2007). These
observations suggest a link between AMPH1 and tau-mediated
neurodegeneration.
In addition to the association with neurodegeneration in
JNPL3 mice and AD, AMPH1 has been implicated in another
neurological disorder known as Stiff-Person Syndrome (SPS)
(Murinson and Guarnaccia, 2008; Geis et al., 2009, 2010).
SPS is classified as an autoimmune disease characterized by
severe spasms and thoracolumbar stiffness due to hypersensitiv-
ity to stimuli such as noise, touch, and emotional distress. SPS
patients are divided in two groups: those with anti-glumatic acid
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decarboxylase (GAD) antibodies and others with anti-AMPH1
antibodies in serum. SPS patients with anti-AMPH1 antibodies
are symptomatically different from anti-GAD positive patients in
that they are older and show severe cervical stiffness. Although
the pathophysiological process that leads to the generation of
anti-AMPH1 positive SPS is still unknown, we hypothesize that
AMPH1 depletion in tauopathy could lead to the secretion or
release of endogenous AMPH1 peptides triggering an autoim-
mune response. This hypothesis laid the foundation to evaluate
the association between auto-AMPH1 antibodies and AMPH1
protein level depletion on the course of neurodegeneration in the
JNPL3 tauopathy mouse model.
MATERIALS AND METHODS
ANIMAL MODEL AND ASSESSMENT OF MOTOR IMPAIRMENT
The JNPL3 mouse model expresses the human tau isoform
0N4R bearing the P301L mutation (hTauP301L), a pathological
molecule in human tauopathies. hTauP301L is commonly found
in post-mortem human brain tissue from patients with fron-
totemporal dementia and parkinsonism linked to chromosome
17 (Lewis et al., 2000). JNPL3 mice develop tau pathology in an
age-dependent and brain region-specific manner (Lewis et al.,
2000). The JNPL3 and non-transgenic (NTg) control mice used
in this study were euthanized at the age reported on Table S1
(supplementary material).
Lewis and McGowan have designed a scale, ranging from 0
to 30, that rates motor dysfunction in JNPL3 mice based on
their performance on tail hang, rope hang, and righting reflex
tests (Lewis and McGowan, 2005). The Lewis and McGowan’s
scale was used to evaluate the motor abilities of JNPL3 hem-
izygous and NTg littermates ranging from 2.9 to 13 months of
age (Table S1 supplementary material). Mice with motor impair-
ment score equal to or below 12 were catalogued as normal,
whereas mice with score 13 or above where catalogued as motor
impaired. For this study, the experiments were performed using
different cohorts based on age and motor impairment score, irre-
spectively of their genotype. This approach allowed us to conduct
the same experiments in cohorts of mice with similar age and
motor impairment score, which contributes to internally validate
the results obtained. It is important to mention that mice in a
cohort were discarded only if the result obtained was identified
as an outlier within the specific cohort used in an experiment.
The University of Puerto Rico animal care and use commit-
tee approved the protocol (403-2006) depicting the experiments
done in this study.
SERA EXTRACTION AND SPINAL CORD PROTEIN LYSATE
PREPARATION
Blood and spinal cords were extracted from euthanized mice.
Blood was allowed to coagulate for 1 h at room temperature.
Afterwards, the coagulated blood was centrifuged at low speed
(2300 × g) for 5min and supernatants stored in aliquots at
−20◦C. Spinal cord protein lysates were prepared by grinding
the tissue in Buffer A (20mM Tris base, pH 7.4, 150mM NaCl,
1mM EDTA, 1mM EGTA, 1mM phenylmethylsulfonyl fluo-
ride, 5mM sodium pyrophosphate, 30mM β-glycerol phosphate,
and 30mM sodium fluoride; volume: five times the wet weight),
followed by centrifugation at 14,000 rpm (21,000 × g) for 10min.
The supernatant was transferred to a clean tube and used for
further analyses.
IMMUNOBLOTS
Immunoblots were conducted as described by De Jesus-Cortes
et al. (2012). Anti-AMPH1 (1:1000; Novus Biologicals, cat. no.
NB110-55455) and anti-GAPDH (1:1000; Abcam, cat. no. 9484)
antibodies were used for densitometric analyses. Tau13 antibody
recognizing human tau (1:50000; Covance, cat. no. MMS-520R-
500) was used to confirm mice genotyping and to assess the
accumulation of pathological tau species in the spinal cords.
Secondary antibodies: HRP-conjugated anti-mouse (Millipore,
cat. no. AP181P) and anti-rabbit (Millipore, cat. no. MAB201P)
antibodies.
INDIRECT ELISA
Sera were subjected to indirect enzyme-linked immunosorbent
assay (ELISA), according to Wilkin et al. (1985). Briefly, the wells
of 96-well microplates (for Figure 3A was used BD Biosciences,
cat. no. 353228; for Figure 3D was used Fisher Scientific, cat.
no. 12565501) were coated with 300 ng of recombinant AMPH1
(Novus Biologicals, cat. no. H00000273-P01) overnight at 4◦C.
Coating efficiency experiments indicated that 300 ng of the anti-
gen per well are sufficient for surface saturation (data not shown).
Non-specific binding was blocked using 3% bovine serum albu-
min in PBS-1X supplemented with 0.05% Tween-20 for 1h at
room temperature. Afterwards, a 1:100 dilution in blocking solu-
tion of each serum was added to each well containing bound
recombinant AMPH1. Anti-mouse IgG antibodies conjugated to
horseradish peroxidase (Millipore, cat. no. 12-349) and colori-
metric HRP substrate (Bio-Rad, cat. no. 172-1064) were used
for the detection of bound auto-AMPH1 antibodies. The back-
ground signal was different in the two types of microplates used.
Therefore, the absorbance detected in the experimental sam-
ples was corrected using the background signal (no antigen)
and normalized to input (recombinant AMPH1 recognized by
FIGURE 1 | AMPH1 protein level decrease in the CNS is accompanied
by increased levels of auto-AMPH1 antibodies in a JNPL3 mouse. (A)
The abundance of AMPH1protein is significantly reduced in the spinal cord
of a JNPL3 mouse in comparison to a non-transgenic (NTg) littermate. (B)
Serum from a JNPL3 mouse with motor impairment and a normal NTg
littermate were collected and used to recognize recombinant AMPH1
(Ponceau). Blots show increased levels of auto-AMPH1 antibodies in the
serum of the JNPL3 mouse that showed AMPH1 protein level reduction in
the spinal cord, but not the serum derived from the NTg mouse.
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anti-AMPH1 commercial antibody instead of sera) as internal
control.
STATISTICAL ANALYSES
ELISA results were subjected to a ROUT outlier test with Q =
0.1% to remove definite outliers. Means were compared by
Two-Way ANOVA (Figures 2B, 3A) and paired two-tailed t-
test (Figure 3D) with a 95% confidence interval. The Pearson’s
correlation test was used to evaluate the association between inde-
pendent variables. Two-tailed P values with a 95% confidence
interval were calculated for every correlation. Statistical analyses
were performed using Graphpad Prism 6.
RESULTS
The immune reaction against proteins or other molecules that are
endogenous (i.e., self-produced) to the organism generates auto-
antibodies (or self-antibodies). These antibodies are indicative of
an actual pathological event thus serving as molecular diagnos-
tic tools. The reduction of AMPH1 protein abundance in JNPL3
mice (De Jesus-Cortes et al., 2012) suggests a putative role in
the pathobiology of tau-mediated neurodegeneration. Based on
the fact that auto-AMPH1 antibodies are used as diagnostic tool
in SPS, we set to study the presence of auto-AMPH1 antibod-
ies in the serum of JNPL3 mice, using recombinant AMPH1 as
“bait.” Serum obtained from a 12 month old terminally ill JNPL3
mouse with reduced abundance of AMPH1 protein in the spinal
cord (Figure 1A) was used for immunoblot assays; serum from a
NTg littermate with normal protein levels of AMPH1 was used
as control (Figure 1A). The results showed that auto-AMPH1
antibodies are readily detected in serum from JNPL3 mice with
reduced abundance of AMPH1 protein, but not in NTg controls
(Figure 1B).
We proceed to evaluate the association between AMPH1 pro-
tein level changes in the CNS and the emergence of auto-AMPH1
antibodies. Lewis et al. (2000) demonstrated that motor impair-
ment progresses with age and correlates with neurodegeneration
in the spinal cords of JNPL3 mice. Motor impairment also corre-
lates with the abundance of tau aggregates known as neurofibril-
lary tangles (NFTs) which are considered to be the pathological
hallmark in AD and related disorders. Thus, motor impairment
in JNPL3 mice is a reliable marker for the progression of tau-
mediated neurodegeneration. Impaired motor behavior includes
slowed or impaired righting when placed supine, dystonia of tail
and hind limbs, abnormal extension of hind legs following tail
elevation, and hunched posture. A motor impairment scale (see
Materials and Methods) was used a behavioral marker to assess
the amount of AMPH1 in the spinal cord and auto-AMPH1
antibodies as the severity of neurodegeneration progressed.
As expected, AMPH1 protein level reduction is associated
with the progression of neurodegeneration in the mouse model
JNPL3 (Figure 2). The results showed thatmotor impaired JNPL3
mice have reduced levels of AMPH1 in comparison to NTg
FIGURE 2 | AMPH1 protein depletion is associated with pathological
events in tau-mediated neurodegeneration. (A) When compared to NTg
controls, JNPL3 mice with impaired motor function show reduced levels of
the protein AMPH1 in the spinal cord, as illustrated by immunoblots. The
protein level reduction is accompanied by the accumulation of 64kDa
hyperphosphorylated hTauP301L. Arrow indicates tau positive bands with a
63.2 kDa molecular weight according to linear semi-logarithmic interpolations.
GAPDH chemiluminescence was used as loading control. (B) Densitometry
analysis of (A). Bar graph shows the mean ± s.e.m. for each group. Means
were compared by two-way ANOVA (p∗∗∗ = 0.0007). (C,D) AMPH1 protein
levels in the spinal cord negatively correlate with motor impairment (C) and
the accumulation of 64kDa hTauP301L (D). The linear regression of the best
fit line shows the 95% confidence band; R2 = 0.3597 for (C) and
R2 = 0.3435 for (D).
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FIGURE 3 | Auto-AMPH1 antibodies are biomarkers of tau-mediated
neurodegeneration in the JNPL3 tauopathy mouse model. (A)
ELISA shows increased levels of auto-AMPH1 antibodies in JNPL3
mice with motor impairment when compared to normal JNPL3 mice
and NTg littermates. Bar graph shows the mean ± standard error of
the mean (s.e.m.) for each group. Means were compared by
two-way ANOVA; p∗∗ = 0.0032, p∗ = 0.0102. (B,C) The amount of
auto-AMPH1 antibodies in serum positively correlates with motor
decline (B) and AMPH1 protein depletion in the CNS (C), as
indicated by the Pearson’s “r” correlation analysis. The linear
regression of the best fit line shows the 95% confidence band;
R2 = 0.3031 for (B) and R2 = 0.1745 for (C). (D) ELISA shows
increased levels of auto-AMPH1 antibodies in old JNPL3 mice (8.1–13
months of age) when compared to NTg littermates. Bar graph shows
the mean ± standard error of the mean (s.e.m.) for each group.
Means were compared by paired two-tailed t-test; p∗ = 0.0378.
mice (Figures 2A,B). The apparent negative correlation between
AMPH1 protein levels and motor impairment was confirmed
statistically (Figure 2C). AMPH1 protein level decrease also cor-
relates with the accumulation of 64 kDa hyperphosphorylated
hTauP301L (Figures 2A,D), a positive indicator of tau pathol-
ogy in JNPL3 mice that concurs with motor dysfunction (data
not shown) and neurodegeneration (Lewis et al., 2000; Sahara
et al., 2002). These observations confirm the association between
AMPH1 protein level reduction and tau-mediated neurodegener-
ation in the JNPL3 mouse model.
Next, we assessed the amount of auto-AMPH1 antibodies as
tauopathy progressed, and its association with motor impair-
ment and AMPH1 protein level depletion. Interestingly, the
amount of AMPH1 increased with the level of neurodegenera-
tion in JNPL3 mice. JNPL3 mice with motor impairment have
higher levels of auto-AMPH1 antibodies than normal JNPL3
and NTg mice (Figure 3A). A positive correlation exists between
the level of auto-AMPH1 antibodies and the severity of motor
impairment (Figure 3B), indicating that as neurodegeneration
progresses more auto-AMPH1 antibodies are detected in serum.
Additionally, the abundance of auto-AMPH1 antibodies was
found to negatively correlate with AMPH1 protein levels in the
spinal cord (Figure 3C), thus providing a link between a neu-
ropathobiological event and an autoimmune response in tau-
mediated neurodegeneration. Finally, we quantified anti-AMPH1
antibodies in sera from old JNPL3 mice and NTg littermates to
assess auto-AMPH1 antibodies as a biomarker of aging. Results
indicate that the signal of auto-AMPH1 antibodies derived from
old and motor impaired JNPL3 mice is significantly higher com-
pared to those found in the sera of NTg age-matched littermates
(Figure 3D). Hence, the emergence of auto-AMPH1 antibodies is
a molecular event associated to tau-mediated neurodegeneration
in JNPL3 mice and not to aging.
DISCUSSION
The adaptive immune system is thought to be a rich source of
biomarkers as it reacts to disease-specific antigens through the
amplification of antibodies that could be detected in blood sam-
ples using relatively non-invasive procedures (Nagele et al., 2011;
Reddy et al., 2011). However, the detection of auto-antibodies
remains controversial for many diseases, including AD. This is,
in part, because the association between the vast majority of
these autoimmune responses and pathobiological processes in
the brain is still unknown, thus questioning their potential as
disease-specific biomarkers. In this regard, we showed the iden-
tification of a novel autoimmune response in association with a
pathobiological event in the CNS of a tauopathy mouse model.
The featured autoimmune response consists of the overpro-
duction of auto-AMPH1 antibodies in motor impaired JNPL3
mice, compared to normal mice and NTg controls (Figures 1B,
3A,D). The abundance of auto-AMPH1 antibodies statisti-
cally correlated with deficiencies in the mice’s motor behavior
(Figure 3B), a phenotype previously demonstrated to be related
to neuronal loss in the spinal cord (Lewis et al., 2000). These
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results identify auto-AMPH1 antibodies as biomarkers of tau-
mediated neurodegeneration in JNPL3 mice. Furthermore, the
abundance of auto-AMPH1 antibodies in blood is associated
with protein level reduction of AMPH1 in the CNS (Figure 3C),
a molecular event linked to pathological events in tauopathy
(Figure 2).
Based on our understanding of how autoimmune responses
generally occur, we can infer that AMPH1 depletion in tauopa-
thy may trigger a response from the immune system leading to
the generation of auto-AMPH1 antibodies that can be detected
in blood. Calpain proteases cleave AMPH1 at specific sites under
neurotoxic conditions and are known to be hyperactive in AD
brains (Camins et al., 2006; Wu et al., 2007). It is plausible to sug-
gest that calpain-mediated cleavage of AMPH1 could lead to the
release of proteolytic peptides that activate an immune response.
Therefore, the detection of AMPH1 depletion in AD brains (De
Jesus-Cortes et al., 2012) suggests that auto-AMPH1 antibodies
could be a putative pathological biomarker.
Altogether, the results indicate that the reduction of AMPH1
protein and the detection auto-AMPH1 antibodies are a conse-
quence or byproduct of tau-mediated neurodegeneration in the
tauopathy mouse model JNPL3. The results also suggest that
auto-immune responses could be an intrinsic component of tau-
mediated neurodegeneration. Nevertheless, further experiments
are needed to understand the molecular mechanisms that lead
to the generation of auto-AMPH1 antibodies and its role in the
pathobiology of tau-mediated neurodegeneration.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/journal/10.3389/fnins.2013.
00277/abstract
Dr. John F. Engelhardt kindly provided serum and spinal cord
from three mSOD1 mice in a terminal study that used an unspec-
ified drug. The mSOD1 mice showed severe motor impairment
regardless of the drug treatment, indicating that the drug did not
have an effect in the progression of neurodegeneration in this ALS
mouse model. The results showed that AMPH1 is readily detected
in terminally ill mSOD1 mice (Figure S1) and there is a weak
detection of anti-AMPH1 antibodies after overexposure of the
western blot membrane in only one of the terminally ill mSOD1
mice tested (Figure S2). Although these results suggest that in an
ALS mouse model with motor impairment there is not reduction
of AMPH1 protein and no detection of anti-AMPH1 antibodies
in the serum, further experiments are required to validate these
observations.
Figure S1 | AMPH1 protein level in the spinal cord of terminally-ill mSOD1
ALS model.Western blot analysis was performed to detect AMPH1 and
tau proteins in spinal cord protein extract from three different mSOD1
mice (e.g., ALS #1). Actin was used as loading control. The detected
proteins are indicated at the right of the panel.
Figure S2 | No detection of anti-AMPH1 antibodies in terminally-ill mSOD1
ALS model. The serum was obtained from the same mice used in
Figure S1. The sera were used as primary antibody in a western blot
assay where the antigen was recombinant GST-AMPH1. Two different
exposures are shown to illustrate the different level of detection between
the serum from JNPL3 mice and that from mSOD1 mice. Ponceau stained
membrane are shown as loading control.
Table S1 | Description of mice used. The table described the genotype,
gender, age and motor impairment score of all mice used in the study.
Mice were divided in three groups: (1) littermates—mice from the same
progeny (brothers and sisters); (2) age-matched—mice that were paired
based on their age at the time of euthanizing; (3) not matched—unpaired
mice that were included in the respective age groups.
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